Pepinemab (Anti-SEMA4D) in Combination with Ipilimumab or Nivolumab for Patients with Resectable Pancreatic and Colorectal Cancer

Authors :: Gregory B. Lesinski
Christina Wu
Hanna Hong
Jonathan M. Hernandez
Tahsin M Khan
Alexander J Rossi
Source :: Annals of Surgical Oncology. 28:4098-4099
Publication Year :: 2021
Publisher :: Springer Science and Business Media LLC, 2021.

Subjects :: Oncology
medicine.medical_specialty
Colorectal cancer
business.industry
MEDLINE
Ipilimumab
medicine.disease
Surgical oncology
Internal medicine
medicine
Surgery
Nivolumab
business
medicine.drug

Tools